Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R

Journal de Pharmacie de Belgique

Volumn 52, Issue 2, 1997, Pages 88-96

  Traxler, Peter ^a   Furet, Pascal ^a   Mett, Helmut ^a   Buchdunger, Elisabeth ^a   Meyer, Thomas ^a   Lydon, Nicholas ^a  

^a CIBA GEIGY LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4,5 BIS(4 FLUOROANILINO)PHTHALIMIDE; 4,5 DIANILINOPHTHALIMIDE; ANTINEOPLASTIC AGENT; CGP 59326; CGP 60261; CGP 62706; EPIDERMAL GROWTH FACTOR RECEPTOR; PHTHALIMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BINDING SITE; COMPUTER MODEL; CONFERENCE PAPER; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; MOUSE; NONHUMAN; TUMOR;

ADENOSINE TRIPHOSPHATE; ANIMALS; BINDING SITES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0030974167     PISSN: 00472166     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Aaronson, S.A. Growth Factors and Cancer. Science 1991, 254, 1146-1152.
2. Hanks, S.K.; Quinn, A.M.; Hunter, T. The protein kinase family: conserved features and phytogeny of the catalytic domains. Science 1988, 241, 42-52.
3. Ullrich, A.; Schlessinger, J. Signal Transduction by Receptors with Tyrosine Kinase Activity. Cell 1990, 61, 203-212.
4. Elder, J.T.; Fisher, G.J.; Lindquist, P.B.; Bennett, G.L.; Pittelkow, M.R.; Coffey, R.J.; Ellingsworth, L.; Derynck, R; Voorhees, J.J. Overexpression of transforming growth factor α in psoriatic epidermis. Science 1989, 243, 811-814.
5. Burke, T.R. Protein-Tyrosine Kinase Inhibitors. Drugs Future 1992, 17, 119-131.
6. Fry, D.W. Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors. Exp. Opin. Invest. Drugs 1994, 3(6). 577-595.
7. Levitzki, A.; Gazit, A. Tyrosine Kinase Inhibition: An Approach to Drug Development. Science 1995, 267, 1782-1788.
8. Traxler, P.; Lydon, N. Recent Advances in Protein Tyrosine Kinase Inhibitors, Drugs Future 1995, 20(12), 1261-1274.
9. Spada, A.P.; Myers, M.A. Exp.Opin.Ther.Patents 1995, 5, 805-817.
10. Bridges, A.J. The current status of tyrosine kinase inhibitors: do the diarylamine inhibitors of the EGF receptor represent a new beginning ? Exp.Opin.Ther.Patents 1995, 5 (12), 1245-1257.
11. Trinks, U.; Buchdunger, E.; Furet, P.; Kump, W.; Mett, H.; Meyer, Th.; Müller, M.; Re-genass, U.; Rihs, G.; Lydon, N.; Traxler, P. Dianilinophthalimides: Potent and Selective, ATP-Competitive Inhibitors of the EGF-Receptor Protein Tyrosine Kinase. J. Med.Chem. 1994, 37, 1015-1027.
12. Buchdunger, E.; Trinks, U.; Mett, H.; Regenass, U.; Müller, M.; Meyer, Th.; McGlynn, E.; Pinna, L.A.; Traxler, P.; Lydon, N.B. 4,5-Dianilinophthalimide: A protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc. Natl.Acad. 1994, 91, 2334-2338.
13. Buchdunger, E.; Trinks, U.; Mett, H.; Regenass, U.; Müller, M.; Meyer, Th,; Beilstein, P.; Wirz, B.; Schneider, P.; Traxler, P.; Lydon, N.B. 4,5-Bis(4-fluoroanilino)-phthalimide: a selective inhibitor of the EGF receptor signal transduction pathway with potent in vivo antitumor activity. Clin. Canc.Res. 1995, 1, 813-821.
14. Traxler, P.; Lydon, N. Recent Advances in Protein Tyrosine Kinase Inhibitors, Drugs Future 1995, 20(12), 1261-1274.
15. Onoda, T.; Inuma, H.; Sasaki, Y.; Hamada, M.; Isshiki, K.; Naganawa, H.; Takeuchi, T. Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus. J. Nat.Prod. 1989, 52 (6), 1252-1257.
16. Dolle R. E.; Dunn, J. A.; Bobko, M.; Singh, B.; Kuster, J. E.; Baizman, E.; Harris, A.L.; Sawutz, D. G.; Miller, D.; Wan., S.; Faltynek, C. R.; Xie, W.; Sarup, J.; Bode D. C.; Pagani, E. D.; Silver, P. J. 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a Potent and Selective Inhibitor of Human Vascular P-Type Platelet-Derived Growth Factor Receptor Tyrosine Kinase.J. Med.Chem. 1994, 37, 2627-2629.
17. Maguire, M.P.; Sheets, K.R.; McVety, K.; Spada, A.P.; Zilberstein, A. A. New Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Substituted Quinoline Derivatives. J. Med.Chem 1994, 372, 129-137.
18. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, Th.; Müller, M.; Regenass, U.; Lydon, N. B. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. USA 1995, 92, 2558-2562.
19. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, Th.; Müller, M.; Druker B.; Lydon, N. B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996, 56, 100-104.
20. Barker, A.J.; Davies, D.H.; Brown, D.S.; Woodburn, J.R.; Green, L.R.; Carlidge, S.A.; Wakeling, X. Structure activity relationships of 4-anilinoquinazolines as inhibitors of EGFR-tyrosine kinase activity. Ann. Onc. 1994, Suppl. 5, 98 (abst. 120).
21. Ward, W.H.J.; Cook, P.N.; Slater, A.M.; Davies, D.H.; Holdgate, G.A.; Green, L.R. Epidermal growth factor receptor tyrosine kinase.Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 1994, 48 (4), 659-666.
22. Fry, D.W.; Kraker, A.J.; McMichael, A.; Ambroso, L.A.; Nelson, J.M.; Leopold, W.R.; Connors, R.W.; Bridges, A.J. A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase. Science 1994, 265, 1093-1095.
23. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H.; Cody, D. R.; McMichael, A.; Fry, D. W. Tyrosine Kinase Inhibitors. 5. Synthesis and Structure-Activity Relationships for 4-(Phenylmethyl-amino]-and 4-(Phenylamino)quinazolines as Potent Adenosine 5′-Triphosphate Binding Site Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor. J. Med. Chem. 1995, 38 (18), 3482-3487.
24. Thompson, A. M.; Bridges, A. J.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine Kinase Inhibitors. 7. 7-Amino-4-(phenylamino)-and 7-Amino-4-[(phenyl-methyl) amino-pyrido[4,3-d]pyrimidines: A New Class of Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor. J. Med. Chem 1995, 38, 3780-3788.
25. Furet, P.: Caravatti, G.; Priestle, J.; Sowadski, J.; Trinks, U.; Traxler, P. Modeling Study of Protein Kinase Inhibitors: Binding Mode of Staurosporine -Origin of the Selectivity of CGP 52 411. J. Comp.-aid. Mol. Design 1995, 9, 465-472.
26. Knighton, D. R., Zheng, J., Ten Eyck, L. F., Ashford, V. A., Xuong, N.-H., Taylor, S. S., Sowadski, J.Crystal Structure of the Catalytic Subunit of Cyclic Adenosine Monophosphate-Dependent Protein Kinase. Science 1991, 253, 407-420.
27. Zheng, J., Knighton, D. R., Zheng, J., Ten Eyck, L. F., Karlsson, R., Xuong, N.-H., Taylor, S. S., Sowadski, J.Crystal Structure of the Catalytic Subunit of cAMP-Dependent Protein Kinase Complexed with MgATP and Peptide Inhibitor. Biochemistry 1993, 32, 2154-2161.
28. Knighton, D. R., Cadena, D. L., Zheng, J., Ten Eyck, L. F., Taylor, S. S., Sowadski, J., Gill, G. N. Structural Features that Specify Tyrosine Kinase Activity Deduded from Homology Modeling of the EGF Receptor. Proc. Natl. Acad. Sci. USA 1993, 90(11), 5001-5005.
29. Traxler, P.; Furet, P.; Mett, H.; Buchdunger, E.; Meyer, Th.; Lydon, N.4-(Phenyl-amino)pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase.J. Med.Chem. 1995, 39, 2285-2292.